Welcome to our dedicated page for ROCKET PHARMACEUTICALS SEC filings (Ticker: RCKTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKET PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKET PHARMACEUTICALS's regulatory disclosures and financial reporting.
Rocket Pharmaceuticals, Inc. officer John Militello reported an open-market sale of 1,157 shares of common stock at an average price of
Rocket Pharmaceuticals CEO Gaurav Shah reported a tax-related stock sale. On February 18, 2026, he sold 5,990 shares of common stock at $3.338 per share to cover tax withholding obligations tied to vesting restricted stock units. After this transaction, he directly holds 1,046,055 common shares, with additional indirect holdings of 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.
Rocket Pharmaceuticals General Counsel Wilson Martin reported an open-market sale of company stock. On February 18, 2026, he sold 1,376 shares of Common Stock at an average price of $3.338 per share in a transaction classified as an open-market sale.
According to the footnotes, the shares were sold to pay tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). After this sale, Martin beneficially owned 682,000 shares, which include RSUs that convert to common stock on a one-for-one basis.
ROCKET PHARMACEUTICALS, INC. General Counsel Wilson Martin sold 12,253 shares of common stock on
Rocket Pharmaceuticals officer John Militello reported an open-market sale of 3,726 shares of common stock at
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah sold 12,279 shares of common stock at $3.312 per share on February 13, 2026 in an open-market transaction. According to the footnotes, the sale was made to cover tax withholding obligations tied to vesting restricted stock units that convert one-for-one into common shares. After this sale, Shah directly holds 1,052,045 shares, and also reports indirect holdings of 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.
Rocket Companies insider sale notice: a Form 144 lists 1,157 common shares related to restricted stock vesting dated
The filing also records prior sales by John Militello: 1,086 shares on
RCKT filing of a Form 144 reports proposed sale of 1,376 common shares tied to restricted stock vesting dated
Issuer reported Form 144 sale notice for restricted shares by an affiliate. The filing lists 5,990 common shares offered for sale related to a restricted stock vesting event on
Rocket Pharmaceuticals insider Martin Wilson has filed a notice to sell 12,253 common shares. The shares were recently acquired through restricted stock vesting on 02/11/2026 as compensation from the issuer. The planned sale through Fidelity Brokerage Services LLC has an aggregate market value of $40,583.16 and is listed for trading on NASDAQ, with an approximate sale date of 02/13/2026. The filing notes that 108,222,228 common shares were outstanding, and also discloses a prior sale of 1,646 shares for $4,909.69 on 11/18/2025.